Evidence map›Paper›PMID 41188628›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Hearing outcome after Cyberknife

Manon Bachelet, Romain Tournegros, Maxime Fieux, Ronan Tanguy, Pierre-Marie Pialat, Fabien Subtil, Stéphane Tringali

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manon BacheletHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, Pierre Bénite cedex, F-69495, France.
Romain TournegrosHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, Pierre Bénite cedex, F-69495, France.
Maxime FieuxHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, Pierre Bénite cedex, F-69495, France. maxime.fieux@chu-lyon.fr.ORCID http://orcid.org/0000-0001-8317-2286
Ronan TanguyCentre Léon Bérard, Radiotherapy, Lyon, France.
Pierre-Marie PialatCentre Léon Bérard, Radiotherapy, Lyon, France.
Fabien SubtilService de biostatistiques de Lyon, Pôle Santé publique, Hospices Civil de Lyon, Lyon, France.
Stéphane TringaliHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, Pierre Bénite cedex, F-69495, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe main objective was to evaluate the hearing impairment of patients after hypofractionated stereotactic radiotherapy (HSRT) by CyberKnife

methodsPatients treated by HSRT with CyberKnife

results71 patients with a 1-year follow-up were included, 55 patients had a 3-year follow-up, and 34 had a 5-year follow-up; the mean follow-up was 43 months (± 24). During the entire follow-up, 89% of the patients (63/71) had hearing impairment, which occurred during the first year for 79% (56/71) of the patients. No risk factor among age, MRI characteristics, and HSRT modalities were found to be associated with hearing impairment in the first year. No relationship was found between tumor volume and hearing impairment.

conclusionFor most patients, HSRT is responsible for hearing impairment within the first year. TRIAL REGISTRATION NUMBER: #20-84 on September the 10th, 2021.

Indexed as

Hearing LossNeuroma, AcousticRadiosurgeryAdultAgedAudiometry, Pure-ToneFemaleFollow-Up StudiesHearingHumansMagnetic Resonance ImagingMaleMiddle AgedRadiation Dose HypofractionationRetrospective StudiesTreatment OutcomeAcoustic neuromaCyberKnife®Hearing lossHypofractionated stereotactic radiotherapyMRIVestibular schwannomaVolumetric analyses

Identifiers

PMID41188628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.